Abbvie Inc
NYSE: ABBV
$164.99
-$4.64 (-2.7%)
Closing Price on November 15, 2024
ABBV Articles
The September 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include AbbVie, Gilead, Johnson & Johnson, Potash, Schlumberger, Visa and Walmart.
Published:
Last Updated:
courtesy of Jon OggStocks were indicated to open higher on Monday after hitting all-time highs the prior week. The one trend that has been proven time after time in this eight-year bull market is...
Published:
Last Updated:
While it seems everything is fully priced, the good news for investors is that there is still a plethora of stocks that are cheaper than the overall S&P 500.
Published:
Last Updated:
AbbVie shares made a handy gain on Thursday after it was announced that the company resolved its Humira patent disputes with Amgen.
Published:
Last Updated:
The September 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include Albermarle, Blue Apron, Box, Dish Network, GM, Transocean and Under Armour.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, Bristol-Myers, Eli Lilly, First Solar, Generac, Oracle, Sirius XM, Southwest and Wendy's.
Published:
Last Updated:
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
Thursday was a mixed day for the U.S. broad markets with all major indices starting off positive, but quickly souring with the exception of the Nasdaq. Crude oil backed off after posting a few days...
Published:
Last Updated:
The August 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks dropped.
Published:
Last Updated:
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
A blockbuster drug is about to get a chance to have even higher sales, as the FDA has expanded its approval of Imbruvica for the treatment of adult patients with chronic graft versus host disease.
Published:
Last Updated:
AbbVie reported better-than-expected second-quarter financial results before the markets opened on Friday.
Published:
Last Updated:
The July 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated: